Selumetinib Fails to Meet PFS End Point in KRAS-mutant NSCLC

Share this content:
SELECT-1 trial of selumetinib as treatment for patients with non-small cell lung cancer did not meet its end point of progression-free survival.
SELECT-1 trial of selumetinib as treatment for patients with non-small cell lung cancer did not meet its end point of progression-free survival.

AstraZeneca announced that the phase 3 SELECT-1 trial of selumetinib as second-line treatment for patients with KRAS mutation-positive non-small cell lung cancer (NSCLC) did not meet its end point of progression-free survival.1

Investigators enrolled 510 patients from over 20 centers. Participants were randomly assigned to receive selumetinib 75 mg orally twice daily or placebo, in combination with docetaxel 75 mg/m2 IV on day 1 of each 21-day cycle.

Adding selumetinib to docetaxel failed to demonstrate a significant effect on survival. The safety profiles of the 2 drugs were consistent with previous reports.

RELATED: Scan-associated Distress May Be Persistent for Patients With NSCLC

Selumetinib is a potent and highly selective MEK 1/2 inhibitor. It is also being developed for the treatment of patients with differentiated thyroid cancer, for which the drug has been granted Orphan Drug Designation, and neurofibromatosis.

AstraZeneca plans to submit the findings for presentation at an upcoming medical meeting.                     

Reference

  1. AstraZeneca provides update on Phase III trial of Selumetinib in non-small cell lung cancer. AstraZeneca website. https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-provides-update-on-Phase-III-trial-of-Selumetinib-in-non-small-cell-lung-cancer-09082016.html. Updated August 9, 2016. Accessed August 24, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters